The Food and Drug Administration Oct. 15 removed epinephrine from the lists of drugs authorized for temporary compounding during the COVID-19 public health emergency by outsourcing facilities and state-licensed pharmacies or federal facilities not registered as outsourcing facilities.

FDA said epinephrine’s removal is based on increased supplies of FDA-approved epinephrine products used to treat hospitalized COVID-19 patients.

Related News Articles

Headline
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce congue lorem nisl, ac dapibus dui vestibulum ut. Vivamus egestas at ipsum eget posuere.…
Headline
Moderna Inc. today announced that its mRNA-1273 vaccine candidate against COVID-19 is 94.5% effective, according to early data. The candidate is currently…
Headline
As of Nov. 6, about 60% of the nation’s retail pharmacies have agreed to participate in a federal program to administer COVID-19 vaccines at no cost to…
Perspective
“Don’t let perfect be the enemy of the good” is a quote credited to the French writer and thinker Voltaire. Although he died in 1778, that phrase is very…
Headline
To continue amplifying the important message of protecting against both the flu and COVID-19, AHA’s Wear A Mask and United Against the Flu campaigns today…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has released guidance on considerations for health…